Read · October 22, 2026

Moderna and Merck's personalized mRNA melanoma vaccine cuts the risk of recurrence or death by 42%, and Moderna shares tumble after the data leaks early

From the LeftCNN: Experimental mRNA vaccine cuts risk melanoma returns by 42%
The Phase 3 result (42% lower risk of recurrence or death with Keytruda), how the tailor-made shot works, a trial patient, the early release after the leak and the stock drop
Grade: F (52/100). Uses loaded words and mixes in the reporter's opinion.
CenterForbes: Moderna Stock Plunges 25% After Apparent Leak of Cancer Vaccine Data
Market story: Moderna down about 26% by 2 p.m. after Phase 3 data surfaced early on Oncology Central, Citi's valuation downgrade, billionaire shareholders' losses
Grade: F (46/100). Mixes in the reporter's opinion and uses loaded words.
From the RightJust the News: Moderna stock plummets after reported leak of disappointing cancer-vaccine data
Moderna closes down nearly 18% after OncologyCentral posted the study early; the 42% and 38% figures, credited to the Wall Street Journal
Grade: D (64/100). Uses loaded words and gets a fact wrong.

Become a Founding Member